和黄医药(00013.HK)治疗肺癌药物新药上市申请已获国家药监局受理并予以优先审评

阿斯达克财经

01-02

和黄医药(00013.HK) 公布，沃瑞沙(ORPATHYS，赛沃替尼/ savolitinib)和泰瑞沙(TAGRISSO ，奥希替尼/ osimertinib)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的新药上市申请已获国家药监局受理并予以优先审评。

沃瑞沙是一种强效、高选择性的口服MET 酪氨酸激酶抑制剂(TKI)。泰瑞沙是一种不可逆的第三代EGFR TKI 。此次受理也将触发一项来自阿斯利康(AZN.US) 的里程碑付款。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)

AASTOCKS新闻

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2500965187"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500965187\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2500965187?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg","is_english":false,"pubTime":"2025-01-02 08:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500965187","market":"sh","top_or_hot":-1,"title":"和黄医药(00013.HK)治疗肺癌药物新药上市申请已获国家药监局受理并予以优先审评","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/HCM\">和黄医药</a>(00013.HK)<span> </span>公布，沃瑞沙(ORPATHYS，赛沃替尼/ savolitinib)和泰瑞沙(TAGRISSO ，奥希替尼/ osimertinib)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的新药上市申请已获国家药监局受理并予以优先审评。<br/><span></span><br/>沃瑞沙是一种强效、高选择性的口服MET 酪氨酸激酶抑制剂(TKI)。泰瑞沙是一种不可逆的第三代EGFR TKI 。此次受理也将触发一项来自<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>(AZN.US)<span> </span><span> </span>的里程碑付款。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>和黄医药(00013.HK)治疗肺癌药物新药上市申请已获国家药监局受理并予以优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013.HK)治疗肺癌药物新药上市申请已获国家药监局受理并予以优先审评\n</h2>\n<h4 class=\"meta\">\n\n\n2025-01-02 08:33 北京时间   <a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407288/latest-news/AAFN\"><strong>阿斯达克财经</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>和黄医药(00013.HK) 公布，沃瑞沙(ORPATHYS，赛沃替尼/ savolitinib)和泰瑞沙(TAGRISSO ，奥希替尼/ osimertinib)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的新药上市申请已获国家药监局受理并予以优先审评。沃瑞沙是一种强效、高选择性的口服MET 酪氨酸...</p>\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407288/latest-news/AAFN\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407288/latest-news/AAFN","article_id":"2500965187","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220520173823854_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500965187","pubTimestamp":1735777980,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"和黄医药公布，沃瑞沙和泰瑞沙的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的新药上市申请已获国家药监局受理并予以优先审评。沃瑞沙是一种强效、高选择性的口服MET 酪氨酸激酶抑制剂。此次受理也将触发一项来自阿斯利康的里程碑付款。沽空资料截至 2024-12-31 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00013":"和黄医药","BK1191":"制药","BK1588":"回港中概股","BK1587":"次新股"},"translate_title":"Chi-Med's (00013. HK) new drug marketing application for the treatment of lung cancer has been accepted by the State Food and Drug Administration and given priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"和黄医药(00013.HK) 公布，沃瑞沙(ORPATHYS，赛沃替尼/ savolitinib)和泰瑞沙(TAGRISSO ，奥希替尼/ osimertinib)的联合疗法用于治疗伴有MET扩增的接受一线表皮生长因子受体(EGFR)抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者的新药上市申请已获国家药监局受理并予以优先审评。沃瑞沙是一种强效、高选择性的口服MET 酪氨酸激酶抑制剂(TKI)。泰瑞沙是一种不可逆的第三代EGFR TKI 。此次受理也将触发一项来自阿斯利康(AZN.US)  的里程碑付款。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0}}}